Trial participants and description
prediabetes
PREDIABETES
The CHORD trial’s priority population was patients with prediabetes receiving care at two PC clinics, the Manhattan campus of the VA NY Harbor Healthcare System (VA), and Bellevue Hospital Center (BH) of New York City’s municipal hospital system [Briefly, all PC clinicians within each site were randomized to intervention or usual care. Eligible patients were seen by one of the study clinicians (at least 1 PC visit in the past 2 years at the VA or at least 3 PC visits in the past 2 years at BH), were between ages 18–75 years, had ≥ 1 glycosylated hemoglobin (HbA1c) between 5.7–6.4% at baseline, no prior DM diagnosis, and ability to communicate in English or Spanish. Two CHWs, members of the study team assigned to each site, consented and enrolled eligible intervention patients, who then completed an intake survey, and began a 12-month intervention during which at least monthly encounters were planned between the CHW and patient. The two CHWs at each site made up to ten attempts to call and enroll each intervention group patient. A successful encounter was defined as when the CHW was able to speak with the patient in-person or by phone, or when a letter or a text message was delivered (no evidence of failure to deliver was apparent). During these encounters, CHWs delivered one or more of four core intervention components.